Medline ® Abstract for Reference 215
Fulminant hepatic failure secondary to erlotinib.
Liu W, Makrauer FL, Qamar AA, Jänne PA, Odze RD
Clin Gastroenterol Hepatol. 2007;5(8):917. Epub 2007 Jul 10.
Erlotinib is a tyrosine kinase inhibitor recently approved by the Food and Drug Administration for the treatment of non-small-cell lung cancer and pancreatic cancer. We report a case of a patient with stage IV non-small-cell lung cancer who died of fulminant hepatic failure as a result of treatment with erlotinib.
Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. firstname.lastname@example.org